News Channels

20 Jan 2021 T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
20 Jan 2021 U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
20 Jan 2021 U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
20 Jan 2021 Turnstone Biologics Acquires Novel Cell Therapy Platform
20 Jan 2021 Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
20 Jan 2021 Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
20 Jan 2021 C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
20 Jan 2021 Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology
20 Jan 2021 Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
20 Jan 2021 Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction
20 Jan 2021 Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration
20 Jan 2021 Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
20 Jan 2021 Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002
20 Jan 2021 Terns Announces FDA Clearance of Investigational New Drug (IND) Application for First-in-Human Phase 1 Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
20 Jan 2021 Apnimed Announces First Patient Dosed in a Second Phase 2 Clinical Trial with AD109, a Disease Modifying Candidate for Obstructive Sleep Apnea
20 Jan 2021 Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial
20 Jan 2021 Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
20 Jan 2021 Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
20 Jan 2021 Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
20 Jan 2021 FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up